| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology,* Academic Medical Center, Amsterdam; and the Department of Pathology, Section of Molecular Pathology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
Both Helicobacter pylori (HP) and Epstein-Barr virus (EBV) have been implicated in carcinogenesis of the stomach. Fifty-seven gastric carcinomas were tested for microsatellite instability and allelic loss at several tumor suppressor loci using 21 polymorphic microsatellite markers. Furthermore, immunohistochemistry for p53 and DPC4/SMAD4 was performed. Results were analyzed according to HP and EBV status of the tumors, as assessed by immunohistochemistry and RNA in situ hybridization, respectively. Fractional allelic loss was lower in EBV-positive carcinomas (n = 15) when compared to EBV-negative carcinomas (P < 0.001). EBV positivity was inversely associated with allelic loss at specific markers on chromosomal arms 5q (APC), 17p (TP53), and 18q (DPC4/SMAD4). Allelic loss at the TP53 locus was not encountered in EBV-positive carcinomas, but occurred in 51% of EBV-negative carcinomas (P < 0.005). Moreover, none of the EBV-positive carcinomas showed unequivocal p53 immunopositivity in contrast to 39% of the EBV-negative carcinomas (P < 0.01). EBV-status was not related to microsatellite instability. There was no correlation between HP-status and any of the molecular alterations tested. In conclusion, EBV-positive gastric carcinomas follow a distinct pathogenesis at the molecular level, in which p53 is not, or differently inactivated.
This article has been cited by other articles:
 |
|
 |
|
  L.-H. Wang, S.-H. Kim, J. H. Lee, Y.-L. Choi, Y. C. Kim, T. S. Park, Y.-C. Hong, C.-F. Wu, and Y. K. Shin Inactivation of SMAD4 Tumor Suppressor Gene During Gastric Carcinoma Progression Clin. Cancer Res., January 1, 2007; 13(1): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cerimele, T. Battle, R. Lynch, D. A. Frank, E. Murad, C. Cohen, N. Macaron, J. Sixbey, K. Smith, R. S. Watnick, et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma PNAS, January 4, 2005; 102(1): 175 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Marsman, R. S. Birjmohun, B. P. van Rees, E. Caspers, G. Johan, A. Offerhaus, P. J. Bosma, J. Jan, and B. van Lanschot Loss of Heterozygosity and Immunohistochemistry of Adenocarcinomas of the Esophagus and Gastric Cardia Clin. Cancer Res., December 15, 2004; 10(24): 8479 - 8485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H H Ishii, G C Gobe, J Yoneyama, M Mukaide, and Y Ebihara Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas J. Clin. Pathol., December 1, 2004; 57(12): 1306 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Lee, M. S. Chang, H.-K. Yang, B. L. Lee, and W. H. Kim Epstein-Barr Virus-Positive Gastric Carcinoma Has a Distinct Protein Expression Profile in Comparison with Epstein-Barr Virus-Negative Carcinoma Clin. Cancer Res., March 1, 2004; 10(5): 1698 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. van Beek, A. zur Hausen, E. Klein Kranenbarg, C. J.H. van de Velde, J. M. Middeldorp, A. J.C. van den Brule, C. J.L.M. Meijer, and E. Bloemena EBV-Positive Gastric Adenocarcinomas: A Distinct Clinicopathologic Entity With a Low Frequency of Lymph Node Involvement J. Clin. Oncol., February 15, 2004; 22(4): 664 - 670. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
